Mereo BioPharma (MREO) Total Non-Current Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has reported Total Non-Current Liabilities for 10 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 20.76% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 20.76% YoY) and the FY2025 annual result came in at $4.3 million, down 70.27% from the prior year.
• Total Non-Current Liabilities advanced to $6.2 million in Q1 2026 per MREO's latest filing, from $4.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for MREO reached as high as $16.6 million in Q2 2024 and fell as low as $1.8 million in Q4 2022.
• A 5-year average of $9.2 million and a median of $7.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 94.84% — and 2023, when it surged 745.23%.
• Year by year, Total Non-Current Liabilities stood at $1.8 million in 2022, then jumped by 745.23% to $15.2 million in 2023, then fell by 3.93% to $14.6 million in 2024, then tumbled by 70.27% to $4.3 million in 2025, then soared by 42.81% to $6.2 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $6.2 million, $4.3 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.